Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)

Stifel analyst Rick Wise reiterated a Hold rating and $87.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst commented, “In one of Medtronic's most news-packed quarters in recent memory, the F4Q25 (Apr.) earnings report left us with a lot to ponder...and multiple crosscurrents to consider. At a high level, the F4Q revenue growth and EPS performance optics were positive: the company beat both Stifel/Consensus top and bottom line projections, as highlighted in our Exhibit 3. As well, Medtronic offered up an initial ~5% F2026 organic growth outlook, better than the 4.5% we modeled. Unsurprisingly, tariffs are expected to pressure the year-ahead F2026 EPS outlook and represent a $200 million to $350 million COGS headwind. Still, MedTech tariff impacts are now expected and understood by the investment community. As we illustrate in Exhibit 2, our F2026 EPS projections are moving lower to reflect the negative tariff impacts. That said, despite the higher-than-expected year-ahead revenue growth outlook, the F2026 year appears more of a transition period than perhaps investors were anticipating.”

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $84.41 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'